The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Investigating ibrutinib for CLL: IciCLLe & CLARITY
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, discusses the results of Bloodwise’s Trials Acceleration Programme (TAP) IciCLLe (ISRCTN12695354) and CLARITY (ISCRTN13751862) studies, investigating the safety and efficacy of ibrutinib for patients with chronic lymphocytic leukemia (CLL). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Hillmen describes the high response rates, MRD results and toxicity profile of ibrutinib in a range of settings.
